Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

OBJECTIVES: The current gold-standard for the first-line treatment in IIIb/IV stages of epithelial ovarian cancer (EOC) is the combination of carboplatin and paclitaxel plus bevacizumab in some countries. In the era of personalized medicine, there is still uncertainty on the impact of several molecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Staropoli, Nicoletta, Ciliberto, Domenico, Chiellino, Silvia, Caglioti, Francesca, Del Giudice, Teresa, Gualtieri, Simona, Salvino, Angela, Strangio, Alessandra, Botta, Cirino, Pignata, Sandro, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347729/
https://www.ncbi.nlm.nih.gov/pubmed/27764790
http://dx.doi.org/10.18632/oncotarget.12633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347729/
https://www.ncbi.nlm.nih.gov/pubmed/27764790
http://dx.doi.org/10.18632/oncotarget.12633

Ejemplares similares